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□ CASE REPORT □
Chronic Graft-versus-host Disease Presenting with Multiple
Punctate Intracranial Lesions on Contrast-enhanced
Magnetic Resonance Imaging
Makoto Terada 1, Kiyotaka Nakamagoe 1, Naoshi Obara 2, Shinichi Ogawa 2,
Noriaki Sakamoto 3, Taiki Sato 4, Seitaro Nohara 1, Shigeru Chiba 2 and Akira Tamaoka 1
Abstract
Central nervous system graft-versus-host disease can present quite a diagnostic challenge. We herein pre-
sent a case of histologically-confirmed chronic graft versus host disease (GVHD) involving the central nerv-
ous system that occurred at 19 months after peripheral blood stem cell transplantation. Cranial magnetic reso-
nance imaging showed areas of confluent hyperintensity in the deep/subcortical white matter with multiple
punctate and curvilinear gadolinium enhancements, suggesting the disruption of the blood-brain barrier. A
brain biopsy revealed perivascular CD3-positive T cell infiltration around the small vessels. We propose that
the detection of punctate-enhanced lesions by magnetic resonance imaging may be a useful finding that facili-
tates the early diagnosis of chronic GVHD involving the central nervous system.
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Introduction
Hematopoietic cell transplantation (HCT), including bone
marrow transplantation (BMT) and peripheral blood stem
cell transplantation (PBSCT), is important in the treatment
of hematologic malignancies and connective tissue diseases.
As the number of patients receiving HCT has increased, re-
ports on the association between neurological complications
and HCT have also increased. Neurological complications
after HCT may be caused by various factors, including the
primary disease, post-transplant lymphoproliferative disease
(PTLD), drug- or radiation-induced effects, and opportunis-
tic infections due to immunosuppression. Chronic graft ver-
sus host disease (GVHD), which most often involves the
skin, eyes, oral mucosa, lungs, gastrointestinal tract and
liver, can also cause neurological complications. Although
the National Institute of Health’s working group on chronic
GVHD acknowledges that the neuromuscular manifestation
of chronic GVHD only involves the muscle, neuromuscular
junctions, and peripheral nerves (1), the number of reported
cases of chronic GVHD that involve the central nervous sys-
tem (CNS-cGVHD) has increased in recent years. This pa-
per reports a case of CNS-cGVHD that occurred at 19
months after PBSCT, which was performed to treat acute
myeloid leukemia (AML). The correlations between the ra-
diological and pathological characteristics are useful for di-
agnosing CNS-cGVHD. This paper discusses the present
case in detail and refers to previous studies.
Case Report
A 46-year-old right-handed woman was admitted to the
hospital with pancytopenia. She had received chemotherapy
(cyclophosphamide, doxorubicin, and 5-fluorouracil) 8 years
previously for a left breast carcinoma. Bone-marrow aspira-
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Figure　1.　Cranial MRI. (A) A T2-weighted image (TR/TE=3,000.0/80.0 ms). High-intensity plaque 
lesions are evident in the bilateral cerebral white matter, predominantly on the left side. (B, C) A 
gadolinium-enhanced T1-weighted image (TR/TE=6.0/2.3 ms). These lesions are enhanced with gado-
linium, especially in the perivascular sites (red arrows). No gadolinium enhancement of the meninges 
was detected. (D, E) A diffusion-weighted imaging (DWI) and an apparent diffusion coefficient (ADC) 
map (b=1,000 s/mm2, TR/TE=5,000.0/65.0 ms). Both DWI and the ADC map show increased values in 
the involved areas. (F) A T2-weighted image (TR/TE=3,000.0/100.0 ms) after steroid pulse therapy. 
The high-intensity lesions of the white matter were significantly reduced. R: right
tion and biopsy revealed hypercellular marrow with an in-
creased number of blasts (15.2%). The patient was therefore
diagnosed with therapy-related myelodysplastic syndrome (t-
MDS). She subsequently progressed to t-AML (French-
American-British classification M0) and received idarubicin
(IDR) and cytarabine (Ara-C) to induce remission. At five
months after the initial diagnosis, the patient underwent allo-
geneic PBSCT (allo-PBSCT) from a one-allele mismatched
related donor after preparation with cyclosporine A (CyA)
and total body irradiation (TBI). Full engraftment was con-
firmed on day 16. The initial post-transplant course was
complicated by acute oral, gastrointestinal tract, and skin
GVHD that resolved after treatment with prednisolone
(PSL), CyA, and methotrexate (MTX). At five months after
PBSCT, the patient developed chronic pulmonary GVHD in
the form of bronchiolitis obliterans organizing pneumonia
(BOOP). She was treated with oral PSL, which was tapered
after achieving a good result.
At 19 months after PBSCT, the patient developed head-
ache, night sweats, difficulty writing due to shaking hands,
and memory loss. Her blood test results were normal. Cere-
brospinal fluid (CSF) studies revealed pleocytosis (33.3×106/
L), protein elevation (85 mg/dL), and low CSF glucose (45
mg/dL), while the patient was negative for oligoclonal IgG
bands and malignant cells. Bacterial and fungal cultures, a
CSF polymerase chain reaction (PCR) for the JC virus, and
tests for Toxoplasma gondii, Cytomegalovirus, Herpes sim-
plex, and Varicella zoster virus were all negative. Magnetic
resonance imaging (MRI) revealed areas of confluent and
asymmetrical hyperintensity on T2-weighted images (T2WI)
and fluid-attenuated inversion recovery (FLAIR) in the bilat-
eral cerebral white matter (Fig. 1A). Gadolinium-enhanced
MRI of the brain revealed multiple punctate and curvilinear
lesions spreading from the deep cerebral region to the sub-
cortical white matter, the pons, and the cerebellar vermis
(Fig. 1B and C). Furthermore, both diffusion-weighted im-
aging (DWI) and apparent diffusion coefficient (ADC) maps
revealed diffuse areas of high-intensity (Fig. 1D and E). MR
angiography (MRA) and susceptibility-weighted imaging
(SWI) revealed normal findings.
Fourteen days after MRI, an open brain biopsy was per-
formed to collect a piece of brain from the patient’s left
frontal lobe white matter. The biopsy revealed the perivascu-
lar infiltration of small, mature lymphocytes in the brain pa-
renchyma, without any signs of inflammatory cell infiltra-
tion into the vessel walls. These infiltrates were mostly
CD3- and CD8-positive on immunostaining. The formation
of granulomas was observed in some portions of the exam-
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Figure　2.　The immunohistological characteristics of brain tissue. A brain biopsy showing perivas-
cular inflammation, which was predominantly located within the brain parenchyma. The inflamma-
tory cells were mainly T lymphocytes with a cytotoxic T-cell immunophenotype, expressing CD3 and 
CD8. No EBV-encoded small RNA (EBER) transcripts were detected by in situ hybridization. Hema-
toxylin and Eosin staining demonstrated non-caseating granulomas containing lymphocytes, histio-
cytes, giant cells, and rare eosinophils. Original magnification, 100×.
ined brain tissue. In situ hybridization for Epstein-Barr Virus
(EBV)-encoded small RNAs (EBERs) was negative (Fig. 2).
Furthermore, no findings indicated the recurrence of the pri-
mary disease. In view of these facts, we diagnosed the pa-
tient as having CNS-cGVHD.
Treatment with three cycles of methylprednisolone pulse
therapy (1,000 mg/day for 3 days) was initiated, which led
to a dramatic improvement in the patient’s cognitive and
neuropsychiatric symptoms. Her brain MRI showed the
shrinkage of the white matter lesions and the disappearance
of the gadolinium-enhanced lesions (Fig. 1F). She was sub-
sequently placed on maintenance therapy with oral PSL and
tacrolimus. Three months after the onset of symptoms, we
confirmed the disappearance of almost all of her neurologi-
cal symptoms.
Discussion
The CNS can be the target organ of GVHD. Approxi-
mately 30 years previously, Rouah et al. first described the
local infiltration of lymphocytes into the CNS in a study of
the autopsied brains of GVHD patients (2). Similar findings
have been reported in recent years using animal models of
chronic GVHD (3, 4). Openshaw and Grauer et al. proposed
the following six criteria for diagnosing CNS-cGVHD: the
occurrence with chronic GVHD affecting other organs, neu-
rological signs of CNS involvement without other explana-
tion, corresponding brain MRI abnormalities, abnormal CSF
studies (pleocytosis, elevated protein or immunoglobulin G,
oligoclonal bands), a pathological brain biopsy or post-
mortem examination, and a response to immunosuppressive
therapy (5, 6). The patient in the present case met all of
these criteria. The exact pathophysiology of chronic GVHD
remains uncertain, and it is often difficult to distinguish
chronic GVHD from other neurological complications. This
may be one reason why only a few cases of CNS-cGVHD
have been reported to date, despite the increasing number of
transplantations that are being performed.
A total of 24 cases of CNS-cGVHD after HCT have been
reported to date. The mean age at the onset of neurological
complications was 32 years (range: 9-63 years), the male-to-
female ratio was 1:0.7, and the median interval between the
time of transplant and the onset of symptoms was 18
months (range: 2-220 months) (7-22). Although many of
these patients suffered from chronic GVHD of other organs
as well, some had chronic GVHD that only involved the
CNS (7-10). The neurological symptoms were diverse, and
included motor paralysis, ataxia, and convulsions. Some pa-
tients presented with only psychiatric symptoms and cogni-
tive dysfunction (9, 11, 12, 14), whereas others presented
with optic neuritis and myelitis, similar to the optic neuritis
and myelitis induced by multiple sclerosis (8, 13).
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Table.　The Characteristics of the Patients with Chronic GVHD of the Central Nervous System after HCT.
Reference 
No. 
Age/ 
Sex 
Primary
disease 
Type of 
HCT 
Post-HCT
period 
(months)
Other 
cGVHD 
Radiological 
findings Pathological findings Therapy Outcome 
7 32/M CML BMT 18 none ND perivascular monocytosis ND dead 
11
9/M AA BMT 8 none CA perivascular CD3+ cell infiltration ND dead 
13/F ALL BMT 3 lungGIT
abnormal 
signaling of 
cerebrum
perivascular CD3+ cell 
infiltration ND dead 
12 43/M CML BMT 18 skin liver WM lesions
brain edema, hematoma, 
multifocal distribution of 
inflammatory infiltrations 
of blood vessel walls and 
perivascular areas
CPM 
PSL improved
14 18/F AML BMT 2 skin leukoencephalopathy; CA angiitis MP Improved
21
44/F ATLL allo- BMT 18 skin 
infiltrating 
lesion in WM 
with CE
parenchymal perivascular 
CD3+ cell infiltration MP Improved
58/F Ph
+ 
B-ALL
allo- 
HCT 15
skin 
GIT
patchy 
WMHs
leptomeningeal 
perivascular CD3+ cell 
infiltration
MP Improved
16 41/M FL allo- HCT 18
skin
mouth  
eyes
multiple 
round lesions 
with CE
perivascular CD3+ cell 
infiltration, noncaseating 
granulomas
Dex 
CyA Improved
15 56/M NHL allo- PBSCT 39
pharynx
eyes 
skin 
liver
multiple T2 
WMHs
perivascular CD3+ cell 
infiltration, activation of 
microglia 
MP
PSL 
MMF
worsened 
10
35/M CML allo- BMT 45
skin 
liver 
multiple T2 
WMHs microangiitis 
PSL
CPM 
MTX
improved
28/F AML allo- BMT 37 none
multiple T2 
WMHs with 
perivascular 
CE
angiitis 
MP
PSL 
CPM 
improved
20/M SCID allo- BMT 220 none
multiple T2 
WMHs; CE at 
meninges
angiitis 
Dex
MP
CPM
improved
33/M CLL allo- BMT 24
skin
liver 
GIT
CA Parenchyma, leptomeningeal angiitis
MP
CPM improved
This case 46/F AML allo- PBSCT 19 lung
multiple T2 
WMHs with 
perivascular 
CE
perivascular CD3+ cell 
infiltration, noncaseating 
granulomas 
MP
PSL 
FK506 
improved
M: male, F: female, AA: aplastic anemia, ATLL: adult-onset T-cell lymphoma, AML: acute myeloid leukemia, B-ALL: B-cell acute lymphoblastic 
leukemia, BMT: bone marrow transplantation, CA: cerebral atrophy, CDVP: combination therapy of cisplatin, dacarbazine, vinblastine, and predniso-
lone, CE: contrast enhancement, CHOP: combination therapy of cyclophosphamide, doxorubicin, vincristine, and prednisolone, CLL: chronic lym-
phocytic leukemia, CML: chronic myelocytic leukemia, CPM: cyclophosphamide, CyA: cyclosporin A, Dex: dexamethasone, FK506: tacrolimus, FL: 
follicular lymphoma, GIT: gastrointestinal tract, HCT: hematopoietic cell transplantation, HIAs: hyperintense areas, MMF: mycophenolate mofetil, 
MP: methylprednisolone, ND: not described, NHL: Non-Hodgkin lymphoma, WM: white matter, WMH: white matter hyperintensity, PBSCT: periph-
eral blood stem cell transplantation, PSL: prednisolone, SCID: severe combined immunodeficiency disease, T2: T2-weighted imaging
Only 13 biopsy- or autopsy-confirmed cases have been re-
ported (Table). The histological features can be categorized
into three types: cerebral vasculitis, encephalitis, and demye-
lination. The most common feature is the infiltration of
CD3-positive T cell-dominant inflammatory cells in the peri-
vascular space or within the vessel wall, whereas only scat-
tered infiltrates were observed in brain parenchyma. Most of
these inflammatory cells were CD8-positive cytotoxic T
cells. The infiltration of CD68-positive monocytes/micro-
glia (10) and human leucocyte antigen (HLA)-DR-positive
microglia has also been reported (15). The use of a short
tandem repeat (STR) analysis (14) or a sex chromosome
analysis (10) to demonstrate donor-derived lymphocyte infil-
tration has also been reported to be useful for diagnosing
chronic GVHD.
Brain MRI often revealed multiple hyperintense lesions,
showing signs of healing, that were predominantly located
in the white matter, particularly in common sites of lacunar
Intern Med 56: 363-368, 2017 DOI: 10.2169/internalmedicine.56.7329
367
infarction (12). There is also a report of a patient with
chronic GVHD who presented only brain atrophy at an ear-
lier stage of the disease (14). After hematopoietic cell trans-
plantation, leukoencephalopathy can also be caused by many
immunosuppressants, radiation therapy, and opportunistic in-
fections. The magnetic resonance appearance of these forms
of toxic leukoencephalopathy involves symmetric hyperin-
tense lesions in the white matter on T2WI and FLAIR,
which are associated with the foci of restricted diffusion
within these areas. Typically, there is no associated contrast
enhancement (23). The perivascular spaces (Virchow-Robin
spaces) are not normally enhanced with gadolinium (24). In
the present case, punctate and curvilinear gadolinium en-
hancement (PCGE) was found along the path of the perfo-
rating medullary arteries. Similar findings were also reported
by Sostak et al (10). PCGE may be seen when the blood-
brain barrier (BBB) of the small vessels is disrupted, either
by the direct injury of the endothelial cells or by angiocen-
tric infiltrates composed of various combinations of T lym-
phocytes, B lymphocytes, and histiocytes. A brain biopsy
should be performed to determine the phenotypes of the in-
filtrating cells and assess EBV reactivation to distinguish be-
tween posterior reversible encephalopathy syndrome
(PRES), primary angiitis of the CNS (PACNS), demyelinat-
ing disease, immune reconstitution inflammatory syndrome
(IRIS), lymphomatoid granulomatosis (LYG), and chronic
lymphocytic inflammation with pontine perivascular en-
hancement responsive to steroids (CLIPPERS) (25). The
pathogenesis of CNS-cGVHD may be similar to these dis-
eases, as is indicated by their similar radiological findings.
In recent years, integrins have also been implicated in the
pathogenesis of intestinal GVHD. Anti-alpha4 integrin ther-
apy has now been approved by the Food and Drug Admini-
stration (FDA) for the treatment of multiple sclerosis and in-
flammatory bowel disease. Drugs that block the infiltration
of leukocytes via the BBB could also be effective for CNS-
cGVHD.
The post-transplantation survival periods are expected to
increase with advancements in transplantation technology. It
is important to bear in mind that patients receiving HLA-
mismatched transplantation, patients with a history of cal-
cineurin inhibitor-induced immune suppression, and patients
receiving TBI, whole-brain irradiation, or intrathecal injec-
tions are at risk for developing late-onset neurological com-
plications. As a result, neuropsychological tests must occa-
sionally be performed to closely monitor the higher brain
function and neurological symptoms of these patients (26).
Chronic GVHD is particularly difficult to diagnose because
it can develop over years and sometimes only involves the
CNS. MRI is useful for detecting distinct lesions that are lo-
calized to the CNS. In other words, MRI gives us a clue as
to whether a brain biopsy is required for a patient who is
suspected of having chronic GVHD; this makes MRI the
key to facilitating the early and definitive diagnosis of
chronic GVHD and to delivering effective treatment in a
timely manner.
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